PRME Average Annual Return 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into PRME


Also see:
PRME stock yearly return 2022
PRME stock yearly return 2023
PRME YTD return
Compare PRME average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
Start date: 10/20/2022
End date: 10/11/2024
Start price/share: $15.37
End price/share: $3.64
Dividends collected/share: $0.00
Total return: -76.32%
PRME Average Annual Return: -51.72%
Starting investment: $10,000.00
Ending investment: $2,368.46
Years: 1.98


PRME average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
Prime Medicine is a biotechnology company committed to delivering a class of differentiated one-time curative genetic therapies, Prime Editors, to address a spectrum of diseases by deploying Prime Editing technology. Co.'s in-licensed Prime Editing technology has the ability to repair mutations. Prime Editors have two main components that act together to edit deoxyribonucleic acid (DNA): a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme, and a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The PRME average annual return since 2022 is shown above.

The Average Annual Return on the PRME average annual return since 2022 page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether PRME average annual return since 2022 or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the PRME average annual return calculation with any dividends reinvested as applicable (on ex-dates).
Quotes delayed 20 minutes

Email EnvelopeFree PRME Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Prime Medicine (PRME) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

PRPH Average Annual Return
PRPO Average Annual Return
PRTA Average Annual Return
PRVA Average Annual Return
PSNL Average Annual Return
PSTV Average Annual Return
PSTX Average Annual Return
PTCT Average Annual Return
PTGX Average Annual Return
PTIX Average Annual Return
More Healthcare companies »

 

PRME Average Annual Return 10 Years | www.AverageAnnualReturn.com | Copyright © 2021 - 2024, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.